AdvanTIG-302 BGB-A317-A1217-302

Recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Beigene Study ID info

AdvanTIG-302 BGB-A317-A1217-302

ClinicalTrials.gov ID info

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents